MapLight Therapeutics, Inc.(MPLT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Unusual Activity in MPLT
Events flagged as statistical outliers against MPLT's own multi-year baseline — not fixed dollar thresholds.
- Record insider buy2026-08-14
Largest insider buy on record for MPLT: Catalyst4, Inc. purchased $50,072,000
View source filing → - Insider cluster2026-08-14
2 insiders bought $98,863,650 of MPLT in 30 days — 3.7σ above this company's 2-year norm
View source filing → - Record insider buy2026-07-30
Largest insider buy on record for MPLT: Catalyst4, Inc. purchased $13,000,000
View source filing → - Insider cluster2026-07-30
2 insiders bought $15,463,496 of MPLT in 30 days — 3.8σ above this company's 2-year norm
View source filing →
MPLT Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for MapLight Therapeutics, Inc. (MPLT), a Healthcare sector company. MPLT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), MapLight Therapeutics, Inc. reports net income of $-60.2M, free cash flow of $-44.9M. Top institutional holders of MPLT by reported 13-F value include Novo A/S, FCPM III SERVICES B.V., T. Rowe Price Investment Management, based on the most recent SEC filings. MPLT trades on the Nasdaq exchange and files with the SEC under CIK 1770069. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MPLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MapLight Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-60.2M
Free Cash Flow
Q2 2026
$-44.9M
ROIC
Q2 2026
-73.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-107.7% YoYOperating Income
-103.8% YoYEPS (Diluted)
+82.4% YoYTotal Assets
+250.2% YoYOp. Cash Flow
-75.3% YoYFree Cash Flow
-74.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Income | $-161.2M -107.7% | $-77.6M | — |
| Operating Income | $-169.1M -103.8% | $-82.9M | — |
| EPS (Diluted) | $-18.56 +82.4% | $-105.38 | — |
| Total Assets | $479.5M +250.2% | $136.9M | — |
| Operating Cash Flow | $-138.1M -75.3% | $-78.8M | — |
| Free Cash Flow | $-138.6M -74.2% | $-79.6M | — |
Get alerted when MPLT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MapLight Therapeutics, Inc. including:
Top Institutional Holders of MPLT
Novo Holdings A/S
$132.1M3,686,622 shFCPM III SERVICES B.V.
$115.6M3,226,400 shT. Rowe Price Investment Management, Inc.
$99.7M2,781,728 shGOLDMAN SACHS GROUP INC
$69.8M1,948,312 shPRICE T ROWE ASSOCIATES INC /MD/
$51.0M1,422,935 shBlackRock, Inc.
$36.7M1,025,134 shNan Fung Group Holdings Ltd
$34.8M971,253 sh5AM Venture Management, LLC
$34.0M950,011 shSanofi
$32.7M912,041 shSTATE STREET CORP
$30.5M852,150 sh
| Fund | Value | Shares |
|---|---|---|
| Novo Holdings A/S | $132.1M | 3,686,622 |
| FCPM III SERVICES B.V. | $115.6M | 3,226,400 |
| T. Rowe Price Investment Management, Inc. | $99.7M | 2,781,728 |
| GOLDMAN SACHS GROUP INC | $69.8M | 1,948,312 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $51.0M | 1,422,935 |
| BlackRock, Inc. | $36.7M | 1,025,134 |
| Nan Fung Group Holdings Ltd | $34.8M | 971,253 |
| 5AM Venture Management, LLC | $34.0M | 950,011 |
| Sanofi | $32.7M | 912,041 |
| STATE STREET CORP | $30.5M | 852,150 |
More Healthcare Companies
View all Healthcare →Put MPLT on your watchlist
Track score changes the day MapLight Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MPLT a good stock to buy?
13F Pro's AI-powered analysis of MapLight Therapeutics, Inc. (MPLT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MPLT are available on the MPLT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MPLT is classified as a small company.
Which hedge funds own MPLT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MPLT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MapLight Therapeutics, Inc.'s investment landscape.